CL2022002804A1 - Análogos del nucleósido bicíclico y monocíclico para el tratamiento de la hepatitis e. - Google Patents

Análogos del nucleósido bicíclico y monocíclico para el tratamiento de la hepatitis e.

Info

Publication number
CL2022002804A1
CL2022002804A1 CL2022002804A CL2022002804A CL2022002804A1 CL 2022002804 A1 CL2022002804 A1 CL 2022002804A1 CL 2022002804 A CL2022002804 A CL 2022002804A CL 2022002804 A CL2022002804 A CL 2022002804A CL 2022002804 A1 CL2022002804 A1 CL 2022002804A1
Authority
CL
Chile
Prior art keywords
bicyclic
hepatitis
treatment
nucleoside analogues
monocyclic nucleoside
Prior art date
Application number
CL2022002804A
Other languages
English (en)
Spanish (es)
Inventor
Tim Hugo Maria Jonckers
Frederik Pauwels
Yannick Debing
Original Assignee
Janssen Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceuticals Inc filed Critical Janssen Pharmaceuticals Inc
Publication of CL2022002804A1 publication Critical patent/CL2022002804A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
CL2022002804A 2020-04-14 2022-10-12 Análogos del nucleósido bicíclico y monocíclico para el tratamiento de la hepatitis e. CL2022002804A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP20169480 2020-04-14

Publications (1)

Publication Number Publication Date
CL2022002804A1 true CL2022002804A1 (es) 2023-03-31

Family

ID=70289599

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2022002804A CL2022002804A1 (es) 2020-04-14 2022-10-12 Análogos del nucleósido bicíclico y monocíclico para el tratamiento de la hepatitis e.

Country Status (15)

Country Link
EP (1) EP4135715B1 (cg-RX-API-DMAC7.html)
JP (2) JP2023522615A (cg-RX-API-DMAC7.html)
KR (1) KR20230002592A (cg-RX-API-DMAC7.html)
CN (1) CN115515603A (cg-RX-API-DMAC7.html)
AR (1) AR121836A1 (cg-RX-API-DMAC7.html)
AU (1) AU2021255809B2 (cg-RX-API-DMAC7.html)
BR (1) BR112022020825A2 (cg-RX-API-DMAC7.html)
CA (1) CA3174790A1 (cg-RX-API-DMAC7.html)
CL (1) CL2022002804A1 (cg-RX-API-DMAC7.html)
ES (1) ES2982564T3 (cg-RX-API-DMAC7.html)
MX (1) MX2022012904A (cg-RX-API-DMAC7.html)
PE (1) PE20230386A1 (cg-RX-API-DMAC7.html)
PH (1) PH12022552679A1 (cg-RX-API-DMAC7.html)
UY (1) UY39172A (cg-RX-API-DMAC7.html)
WO (1) WO2021209419A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024086592A2 (en) * 2022-10-17 2024-04-25 Emory Unversity 4'-halogen containing nucleotide and nucleoside therapeutic compositions and uses related thereto
WO2025014360A1 (en) * 2023-07-07 2025-01-16 Erasmus University Medical Center Rotterdam Guanosine nucleotide analogs for use in preventing and/or treating hepatitis e virus infection

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2952714T3 (es) * 2013-06-26 2023-11-03 Janssen Pharmaceuticals Inc Nucleósidos sustituidos, nucleótidos y análogos de los mismos
US9603864B2 (en) * 2014-06-24 2017-03-28 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
SG11201610597QA (en) * 2014-06-24 2017-01-27 Alios Biopharma Inc Substituted nucleosides, nucleotides and analogs thereof
WO2017210438A1 (en) * 2016-06-03 2017-12-07 Gilead Pharmasset Llc Methods of treating hepatitis e viral infection

Also Published As

Publication number Publication date
CA3174790A1 (en) 2021-10-21
US20230310481A1 (en) 2023-10-05
EP4135715A1 (en) 2023-02-22
AU2021255809B2 (en) 2026-08-06
CN115515603A (zh) 2022-12-23
PH12022552679A1 (en) 2024-04-22
BR112022020825A2 (pt) 2022-11-29
EP4135715B1 (en) 2024-05-08
ES2982564T3 (es) 2024-10-16
MX2022012904A (es) 2023-01-24
AU2021255809A1 (en) 2022-12-15
PE20230386A1 (es) 2023-03-06
UY39172A (es) 2021-10-29
EP4135715C0 (en) 2024-05-08
WO2021209419A1 (en) 2021-10-21
AR121836A1 (es) 2022-07-13
KR20230002592A (ko) 2023-01-05
JP2023522615A (ja) 2023-05-31
JP2026120528A (ja) 2026-07-22

Similar Documents

Publication Publication Date Title
CO2023015484A2 (es) Compuesto, composiciones y métodos para el tratamiento de trastornos
DOP2022000293A (es) Análogos de nucleósido de 1’-ciano y usos de los mismos
ECSP22061711A (es) N4-hidroxicitidina y derivados y usos antivirales relacionados con los mismos
CO2022010330A2 (es) Dosificación de gamma-hidroxibutirato (ghb)
CL2022001719A1 (es) Compuestos moduladores de la diacilglicerol quinasa
CL2023003965A1 (es) Inhibidores cdk2.
CL2023001062A1 (es) Compuestos fosfolípidos y usos de estos
CR20240363A (es) Compuestos y métodos para el tratamiento de infecciones virales.
CO2025003733A2 (es) Compuestos cíclicos de urea tiazolilo para el tratamiento del hsv
CL2020003133A1 (es) Formulación para uso en el tratamiento simultáneo de infecciones provocadas por coccidios y deficiencias de hierro
ECSP18061667A (es) Pirimidinas sustituidas con arilo para su uso en la infección por virus influenza
CL2023003893A1 (es) Semaglutida para el tratamiento de esteatohepatitis no alcohólica.
ECSP21031085A (es) Nuevas 6,7-dihidro-4h-pirazolo[1,5-a] pirazinindol-2-carboxamidas activas contra el virus de la hepatitis b (vhb)
AR115790A1 (es) Apirasas solubilizadas, métodos y usos
CL2022000807A1 (es) Compuesto bicíclico y uso del mismo
DOP2024000172A (es) Compuestos antivirales y métodos de elaboración y uso de los mismos
CO2024012000A2 (es) Compuestos antivirales y métodos de elaboración y uso de los mismos
CO2022014044A2 (es) Pld para uso en combinación con el tratamiento de coronavirus
BR112022020825A2 (pt) Análogos de nucleosídeos bicíclicos e monocíclicos para o tratamento de hepatite e
MX2022016179A (es) Compuestos y metodos para tratar infecciones fungicas.
MX2022010093A (es) Tafoxiparina para el tratamiento de la preeclampsia.
UY40482A (es) Composición líquida de dalbavancina.
UY40481A (es) Composición líquida de dalbavancina
BR112021006388A2 (pt) composto, composição farmacêutica, uso de um composto, e, método para tratamento de uma infecção viral em um mamífero
BR112022020820A2 (pt) Análogos de nucleosídeos alquinílicos para o tratamento de hepatite e